A randomized, double-blinded, placebo-controlled, single-center, comparative study evaluating Phaseolean® safety and efficacy in overweight/obese participants

一项随机、双盲、安慰剂对照、单中心、比较研究,旨在评估 Phaseolean® 在超重/肥胖受试者中的安全性和有效性

阅读:1

Abstract

SCOPE: Phaseolean®, a standardized water extract of Phaseolus vulgaris or white kidney bean, exhibits α-amylase inhibitory property, which decreases calorie absorption by preventing or delaying carbohydrate digestion, thus supporting weight management. This randomized, double-blind, placebo-controlled, single-center comparative study (Clinical trial registration number: CTRI/2023/02/049440, Registered on: February 03, 2023) evaluated the safety and efficacy of Phaseolean® in weight management in overweight or obese participants upon regular intake at two different doses compared with placebo. METHOD: Sixty-six participants were enrolled and randomly divided into three groups, considering the inclusion & exclusion criteria. Each group was assigned a specific daily dosage for three meals: Phaseolean® 1500 mg/day (500 mg per meal), Phaseolean® 3000 mg/day (1000 mg per meal), or placebo 1500 mg/day (500 mg per meal), administered thrice a day before meals for 45 consecutive days. Body weight; body mass index (BMI); skinfold fat thickness; waist, hip, and thigh circumferences; and blood biochemical parameters were monitored and analyzed to evaluate the effects of these interventions. RESULTS AND CONCLUSIONS: Of the 66 enrolled participants, 62 completed the study. Treatment with Phaseolean® 1500 mg/day reduced the weight by an average of 2.10 kg (0.33 kg/week), while that with 3000 mg/day was 1.94 kg (0.30 kg/week); 0.13 kg weight loss (0.02 kg/week) was observed in the placebo group after 45 days, showing significant differences between the Phaseolean® and placebo groups (p < 0.01). BMI, body fat, skinfold fat thickness, and the waist, hip, and thigh circumference were significantly reduced (p < 0.01) in both Phaseolean® groups compared with those in the placebo group, which showed no significant changes.No adverse effects were observed during the clinical trial period. Phaseolean® 1500 mg/day dose was more effective in weight reduction than the 3000 mg/day higher dose. Therefore, Phaseolean® can be used to support healthy weight management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。